DIRA is ultra-rare. With KINERET, his hope doesn't have to be1

KINERET has been demonstrated to be effective for the treatment of DIRA.1


Baby looking at camera, being held by mother

DIRA is an ultra-rare pediatric autoinflammatory disease1

DIRA is an autosomal recessive disorder caused by mutations in the IL1RN gene, leading to loss of production and function of the IL-1Ra.1

  • DIRA generally presents at or near birth and can escalate to life-threatening inflammation2
  • Symptoms of DIRA include swelling of bone tissue, bone pain and deformity, swelling of the tissues around the bones, and skin rash that can cover most of the body3
  • DIRA is often misdiagnosed as infectious osteomyelitis with pustulosis and systemic inflammation, leading to ineffective treatment with antibiotics4
  • DIRA has a 25% mortality rate, and there are currently no known patients who, without treatment, have reached adulthood2
Two overlapping squares that are transparent

A swift diagnosis and initiation of appropriate treatment are essential to improving a DIRA patient’s prognosis.2

Baby looking at camera
Two overlapping squares that are transparent

Learn more about KINERET

KINERET is FDA approved to treat DIRA and in a long-term study was demonstrated to induce inflammatory remission in patients with this painful, life-threatening disease.1

See the data

DIRA is driven by IL-1

  • IL-1 (IL-1α and IL-1β) is a prototypic proinflammatory cytokine2
    • Secretion of IL-1 has an important role in systemic inflammation and in the signs and symptoms of DIRA1,2
  • DIRA is an autosomal recessive monogenic autoinflammatory disease caused by mutations in the IL1RN gene, leading to loss of function and secretion of IL-1Ra1,2
  • The deficiency of IL-1Ra results in unopposed IL-1α and IL-1β proinflammatory signaling, causing severe systemic inflammation with skin and bone involvement1
Learn how KINERET works
Kineret blocks the signal to stop inflammation